Literature DB >> 23540490

Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysis.

Rachit Kumar1, Aaron T Wild, Mark A Ziegler, Ted K Hooker, Samson D Dah, Phuoc T Tran, Jun Kang, Koren Smith, Jing Zeng, Timothy M Pawlik, Erik Tryggestad, Eric Ford, Joseph M Herman.   

Abstract

Stereotactic body radiation therapy (SBRT) achieves excellent local control for locally advanced pancreatic cancer (LAPC), but may increase late duodenal toxicity. Volumetric-modulated arc therapy (VMAT) delivers intensity-modulated radiation therapy (IMRT) with a rotating gantry rather than multiple fixed beams. This study dosimetrically evaluates the feasibility of implementing duodenal constraints for SBRT using VMAT vs IMRT. Non-duodenal sparing (NS) and duodenal-sparing (DS) VMAT and IMRT plans delivering 25Gy in 1 fraction were generated for 15 patients with LAPC. DS plans were constrained to duodenal Dmax of<30Gy at any point. VMAT used 1 360° coplanar arc with 4° spacing between control points, whereas IMRT used 9 coplanar beams with fixed gantry positions at 40° angles. Dosimetric parameters for target volumes and organs at risk were compared for DS planning vs NS planning and VMAT vs IMRT using paired-sample Wilcoxon signed rank tests. Both DS VMAT and DS IMRT achieved significantly reduced duodenal Dmean, Dmax, D1cc, D4%, and V20Gy compared with NS plans (all p≤0.002). DS constraints compromised target coverage for IMRT as demonstrated by reduced V95% (p = 0.01) and Dmean (p = 0.02), but not for VMAT. DS constraints resulted in increased dose to right kidney, spinal cord, stomach, and liver for VMAT. Direct comparison of DS VMAT and DS IMRT revealed that VMAT was superior in sparing the left kidney (p<0.001) and the spinal cord (p<0.001), whereas IMRT was superior in sparing the stomach (p = 0.05) and the liver (p = 0.003). DS VMAT required 21% fewer monitor units (p<0.001) and delivered treatment 2.4 minutes faster (p<0.001) than DS IMRT. Implementing DS constraints during SBRT planning for LAPC can significantly reduce duodenal point or volumetric dose parameters for both VMAT and IMRT. The primary consequence of implementing DS constraints for VMAT is increased dose to other organs at risk, whereas for IMRT it is compromised target coverage. These findings suggest clinical situations where each technique may be most useful if DS constraints are to be employed.
Copyright © 2013 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Duodenal sparing; IMRT; Pancreatic cancer; VMAT

Mesh:

Year:  2013        PMID: 23540490      PMCID: PMC3994664          DOI: 10.1016/j.meddos.2013.02.003

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  22 in total

Review 1.  Locally advanced pancreatic cancer.

Authors:  Christopher G Willett; Brian G Czito; Johanna C Bendell; David P Ryan
Journal:  J Clin Oncol       Date:  2005-07-10       Impact factor: 44.544

2.  A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma.

Authors:  Michael W Brown; Holly Ning; Barbara Arora; Paul S Albert; Matthew Poggi; Kevin Camphausen; Deborah Citrin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-01       Impact factor: 7.038

3.  Single-Arc IMRT?

Authors:  Thomas Bortfeld; Steve Webb
Journal:  Phys Med Biol       Date:  2008-12-10       Impact factor: 3.609

4.  A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy.

Authors:  Luca Cozzi; Ketayun Ardeshir Dinshaw; Shyam Kishore Shrivastava; Umesh Mahantshetty; Reena Engineer; Deepak Dattatray Deshpande; S V Jamema; Eugenio Vanetti; Alessandro Clivio; Giorgia Nicolini; Antonella Fogliata
Journal:  Radiother Oncol       Date:  2008-08-08       Impact factor: 6.280

5.  Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: a treatment planning comparison with fixed field IMRT.

Authors:  Eugenio Vanetti; Alessandro Clivio; Giorgia Nicolini; Antonella Fogliata; Sarbani Ghosh-Laskar; Jai Prakash Agarwal; Ritu Raj Upreti; Ashwini Budrukkar; Vedang Murthy; Deepak Dattatray Deshpande; Shyam Kishore Shrivastava; Ketayun Ardeshir Dinshaw; Luca Cozzi
Journal:  Radiother Oncol       Date:  2009-01-20       Impact factor: 6.280

6.  Dosimetric comparison of volumetric modulated arc therapy and intensity-modulated radiation therapy for pancreatic malignancies.

Authors:  Arif N Ali; Anees H Dhabaan; Christie S Jarrio; Arsalan K Siddiqi; Jerome C Landry
Journal:  Med Dosim       Date:  2011-12-19       Impact factor: 1.482

7.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.

Authors:  Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

8.  Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity.

Authors:  Jerome C Landry; Gary Y Yang; Joseph Y Ting; Charles A Staley; William Torres; Natia Esiashvili; Lawrence W Davis
Journal:  Med Dosim       Date:  2002       Impact factor: 1.482

9.  Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.

Authors:  Daniel T Chang; Devin Schellenberg; John Shen; Jeff Kim; Karyn A Goodman; George A Fisher; James M Ford; Terry Desser; Andrew Quon; Albert C Koong
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

Review 10.  Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review.

Authors:  Florence Huguet; Nicolas Girard; Clotilde Séblain-El Guerche; Christophe Hennequin; Françoise Mornex; David Azria
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

View more
  8 in total

1.  Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.

Authors:  Vivek Verma; Audrey J Lazenby; Dandan Zheng; Abhijeet R Bhirud; Quan P Ly; Chandrakanth Are; Aaron R Sasson; Chi Lin
Journal:  Radiother Oncol       Date:  2017-01-12       Impact factor: 6.280

2.  Individually optimized stereotactic radiotherapy for pancreatic head tumors: A planning feasibility study.

Authors:  Milly Buwenge; Savino Cilla; Alessandra Guido; Lucia Giaccherini; Gabriella Macchia; Francesco Deodato; Silvia Cammelli; Francesco Cellini; Gian C Mattiucci; Vincenzo Valentini; Markus Stock; Alessio G Morganti
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-28

3.  Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.

Authors:  E Gkika; S Adebahr; S Kirste; T Schimek-Jasch; R Wiehle; R Claus; U Wittel; U Nestle; D Baltas; A L Grosu; T B Brunner
Journal:  Strahlenther Onkol       Date:  2017-01-30       Impact factor: 3.621

4.  Dosimetric feasibility on hypofractionated intensity-modulated radiotherapy and simultaneous integrated boost for locally advanced unresectable pancreatic cancer with helical tomotherapy.

Authors:  Feng Teng; Lingling Meng; Fuhai Zhu; Gang Ren
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 5.  Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief.

Authors:  Milly Buwenge; Gabriella Macchia; Alessandra Arcelli; Rezarta Frakulli; Lorenzo Fuccio; Sara Guerri; Elisa Grassi; Silvia Cammelli; Francesco Cellini; Alessio G Morganti
Journal:  J Pain Res       Date:  2018-10-04       Impact factor: 3.133

6.  Variation in accumulated dose of volumetric-modulated arc therapy for pancreatic cancer due to different beam starting phases.

Authors:  Makoto Sasaki; Mitsuhiro Nakamura; Nobutaka Mukumoto; Yoko Goto; Yoshitomo Ishihara; Manabu Nakata; Naozo Sugimoto; Takashi Mizowaki
Journal:  J Appl Clin Med Phys       Date:  2019-09-20       Impact factor: 2.102

7.  Dosimetric and radiobiological comparison of treatment plan between CyberKnife and EDGE in stereotactic body radiotherapy for pancreatic cancer.

Authors:  Zhi-Tao Dai; Li Ma; Ting-Ting Cao; Lian Zhu; Man Zhao; Ning Li
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

Review 8.  A review of stereotactic body radiotherapy - is volumetric modulated arc therapy the answer?

Authors:  Daniel Sapkaroski; Catherine Osborne; Kellie A Knight
Journal:  J Med Radiat Sci       Date:  2015-05-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.